Last reviewed · How we verify
Fosfomycin 3 g
At a glance
| Generic name | Fosfomycin 3 g |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FOsfomycin for Male Urinary Tract Infection (PHASE3)
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women. (PHASE4)
- Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate and D-Mannose to Avoid Symptoms and Prevents Recurrence in Women With Recurrent Urinary Tract Infections (PHASE4)
- Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention (PHASE1, PHASE2)
- Intravenous Fosfomycin Pharmacokinetics Study (PHASE1)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosfomycin 3 g CI brief — competitive landscape report
- Fosfomycin 3 g updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI